Flu Vaccine is the most Dangerous Vaccine in the U. S. based on Settled Cases for Injuries
Attorney Howard Gold of Gold Law Firm, who settled a case for GBS due to a flu vaccine in 2011, remarked:
Petitioners have three (3) years from the onset of the injury (or two years from date of death) to file a claim. Gold states that the “Program is not used as much as it could be because the American public is just not aware of it. I receive at least 5 calls a month from individuals who cannot obtain compensation because the deadline has passed. They just found out about it too late. We all need to do a better job in getting the word out to the public that the Program exists.” (Source.)
In November 2013, a healthy 19-year old young man died from a routine exam that included the flu vaccine. Chandler Webb received the flu shot on October 15th, and then died on November 19th, 28 days later. Since the flu shot is considered safe in the medical field, doctors waited too long to suspect that the flu shot was causing Chandler’s rapidly deteriorating medical condition, according to his mother. She believes that if they had investigated the adverse reaction to the flu shot immediately, he might still be alive today.
Just a quick cursory view of cases that are being compensated by this vaccine court shows that the most cases, by far, are cases for GBS and the flu vaccine.
The U.S Court of Federal Claims provides a referral list of attorneys that specialize in representing clients wanting to file claims for vaccine damages. The list is here, and contains 123 attorneys.
One of the law firms representing clients in the Vaccine Court is Maglio, Christopher, & Toale. This law firm has actually listed cases they have settled in the past couple of years here.
From what appears to be some point in 2010 through 2013, they have settled 132 cases
Preliminary Results: Surveillance for Guillain-Barré Syndrome After Receipt of Influenza A (H1N1) 2009 Monovalent Vaccine — United States, 2009–2010
GBS incidence was calculated and compared for the vaccinated and unvaccinated populations, which were estimated by age group, using data from CDC’s Behavioral Risk Factor Surveillance System (BRFSS) and National 2009 H1N1 Flu Survey (NHFS) telephone survey data for the counties in the EIP catchment areas, using methods published previously (4). The total person-time of follow-up was calculated by multiplying the population under surveillance by the number of days since the start of surveillance, October 1, 2009. Person-time at risk for GBS in the vaccinated population was calculated by multiplying the number of vaccinees by 42 days (or the number of days from vaccination to the end of the surveillance period if <42 days) (1). Children aged 6 months–9 years who received a second dose of 2009 H1N1 vaccine were presumed to have received it 28 days after the first dose, as recommended by the Advisory Committee on Immunization Practices,¶ giving them an additional 28 days of person-time at risk. To calculate the corresponding person-time in the unvaccinated population, the person time at risk for GBS was summed among the vaccinated population and then subtracted from the total person-time of follow-up under surveillance.
Incidence among the vaccinated population was calculated by dividing the number of GBS cases vaccinated within the risk window by the total amount of person-time at risk following vaccination. Incidence among the unvaccinated population was calculated by dividing the number of GBS cases unexposed to vaccine or exposed to vaccine outside the risk window by the total amount of person-time unexposed to 2009 H1N1 vaccine. Bootstrapping methods were used to estimate 95% confidence intervals (CIs) for the rate ratios that incorporated the variance of vaccine coverage estimates (5). A Poisson distribution was assumed for the occurrence of cases and a normal distribution for the vaccine coverage estimates; the Mantel-Haenszel method was used for age-adjusted CIs. A temporal scan statistic was used to assess for any significant clustering in the interval between vaccination and illness onset in vaccinated cases (6).
During October 1, 2009–May 10, 2010, a total of 529 reports of potential GBS were identified by EIP, of which 326 met the GBS case criteria. Of the 326 persons with GBS, 27 had documentation of 2009 H1N1 vaccination in the 42 days preceding illness onset, 274 did not receive vaccine, and the vaccine status of 25 was either unknown (six) or pending ascertainment (19) (Table 1). Sixteen of the 27 (59%) with documentation of 2009 H1N1 vaccination also reported antecedent illness symptoms in the 42 days before GBS onset; 78% of unvaccinated persons with GBS (215 of 274) reported antecedent symptoms (p=0.04). No clustering among vaccinated persons was observed in the period between vaccination and illness onset (p=0.54). Among the 27 GBS patients with 2009 H1N1 vaccination, four required ventilator support, and one remained hospitalized 30 days after GBS onset; among the 274 GBS patients who did not receive 2009 H1N1 vaccination, 37 (14%) required ventilator support, and 34 (12%) remained hospitalized after 30 days. Eight (2%) of the 326 GBS patients died (from any cause); none of the eight had received the 2009 H1N1 vaccine within 42 days of illness onset.
Among patients hospitalized through March 31, 2010, comparison of the incidence of GBS among those who received 2009 H1N1 vaccine and those who did not receive the vaccine revealed an age-adjusted rate ratio of 1.77 (CI = 1.12–2.56) (Table 2). If this preliminary rate ratio is confirmed in end-of-surveillance analyses, the attributable rate of GBS would be 0.71 per 100,000 person-years, corresponding to an attributable risk of 0.8 excess cases of GBS per 1 million vaccinations.**
Risk of Guillain-Barré Syndrome Following H1N1 Influenza Vaccination in Quebec
During the active surveillance period, 61 possible GBS cases were reported to public health authorities. Seventy-seven possible GBS cases were retrospectively identified in the MEDECHO hospital admission database. Thirty-seven cases were found in both sources, for a total of 101 cases. For all 101, medical charts were retrieved and analyzed. Eighteen possible cases were excluded: 12 cases with a final diagnosis other than GBS, 2 recurrent GBS cases, 2 cases with disease onset before October 13, 2009, and 2 other cases with onset after March 31, 2010. Thus, 83 cases were included in the analysis. The overall GBS incidence rate in the study population, representing 3 623 046 person-years of observation, was 2.3 per 100 000.
Of the 83 confirmed GBS cases included in the analysis, 42 had been immunized before disease onset (1-121 days after immunization) and all had received the ASO3 adjuvant H1N1 vaccine. For 25 cases, disease onset was 8 or fewer weeks after the vaccine was administered and they were considered exposed, whereas the 17 other cases were immunized more than 8 weeks before disease onset and were considered unexposed. Thus, for the cohort analysis, 25 GBS cases were considered exposed and 58 cases were considered unexposed.
The characteristics of GBS cases according to exposure status are shown in Table 1. Forty-nine cases were classified in the Brighton level 1 category, 22 cases in level 2, and 12 cases in level 4. The distribution of cases according to diagnostic category was similar in exposed and unexposed cases. The percentage of male patients was 69%. The median age was 49 years (range, 1-89 years). The percentage of elderly patients was higher in the exposed group than the unexposed group. The majority of patients (96%) were hospitalized; 25% developed severe paralysis of the lower limbs and were unable to walk at some point; and 17% developed respiratory distress syndrome and required intubation and/or assisted ventilation. Four patients died, all of whom were older than 60 years. Conditions occurring within 1 month before GBS onset as reported in medical records included a respiratory tract infection or influenzalike illness in 36% of cases, gastroenteritis in 18%, and trauma in 4%. A history of infection during the month prior to hospitalization was less frequent in exposed than in unexposed patients. The median interval between disease onset and hospitalization was 5 days (range, 1-34 days).
Of the 83 confirmed GBS cases identified during the 6-month study period, 56 (67% of total) occurred during a 12-week period from October 18, 2009 (2009 Centers for Disease Control and Prevention [CDC] week 42) to January 9, 2010 (2010 CDC week 1). The cluster was mostly explained by cases occurring in persons who were recently (≤8 weeks) immunized (22/56). Details on the distribution of cases are provided in eFigure 1.